24 recruiting. 24 Phase 3, 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 24 | Recruiting 24 |
| Phase 2 | 4 | Recruiting 4 |
Follow Epilepsy: new trials by email Literature Review of Epilepsy trials Research Report on Epilepsy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy JZP926 capsule, Placebo - Juvenile Myoclonic Epilepsy | Phase 2 / Phase 3 | Recruiting | Jazz Pharmaceuticals | 260 | 2026-09-18 | 2026-11-02 |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures RAP-219, Placebo - Focal Seizure, Epilepsy | Phase 3 | Recruiting | Rapport Therapeutics Inc. | 312 | 2026-09-01 | 2026-10-15 |
| A Study to Evaluate the Safety, Efficacy, and PK of ONO-2017 in Japanese Patients With POS 2 to 17 Year Olds Cenobamate (tablet) for 12 to < 18 year olds, Cenobamate (syrup) for 2 to < 18 year olds - Partial Epilepsy | Phase 3 | Recruiting | Ono Pharmaceutical Co., Ltd. | 20 | 2026-06-10 | 2026-10-09 |
| Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Focal Seizures FOCUS-1 RAP-219, Placebo - Focal Seizure, Epilepsy | Phase 3 | Recruiting | Rapport Therapeutics Inc. | 333 | 2026-06-05 | 2026-10-26 |
| LEvetiracetam to Prevent Seizures in Symptomatic Alzheimer's Disease in Adults With Down Syndrome Levetiracetam 500mg, Placebo - Down Syndrome, Down Syndrome (DS) | Phase 3 | Recruiting | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 120 | 2025-12-22 | 2026-01-12 |
| Levetiracetam Three Times Daily in Epilepsy Levetiracetam - Epilepsy | Phase 3 | Recruiting | Waad Alkathiri | 120 | 2025-10-01 | 2026-03-24 |
| TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders L-serine, Maltodextrin (Placebo) - GRIN-related Disorders, GRIN1 | Phase 3 | Recruiting | Meyer Children's Hospital IRCCS | 40 | 2025-08-29 | 2026-01-29 |
| A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety 1mg elsunersen, 0.5mg elsunersen - Epileptic Encephalopathy, SCN2A Encephalopathy | Phase 3 | Recruiting | Praxis Precision Medicines | 40 | 2025-08-13 | 2026-08-03 |
| An Efficacy and Safety Study of Clemizole HCl in Patients With Lennox-Gastaut Syndrome Clemizole HCl, Placebo - Lennox Gastaut Syndrome | Phase 3 | Recruiting | Epygenix | 260 | 2025-04-09 | 2026-10-09 |
| Cannabidiol as add-on Therapy for Children With Refractory Epilepsy (CBD-uN1que), a High-quality Individualized Approach: a Series of N-of-1 Trials Cannabidiol (CBD) oral solution, Placebo - Refractory Epilepsy in Children, Refractory Epilepsy | Phase 3 | Recruiting | UMC Utrecht | 50 | 2025-02-06 | 2026-06-25 |
| Lemborexant Treatment of Insomnia Linked to Epilepsy Lemborexant, Placebo - Epilepsy, Sleep | Phase 3 | Recruiting | University of Manitoba | 26 | 2024-10-29 | 2025-02-13 |
| A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) XEN1101, Placebo - Focal Onset Seizures | Phase 3 | Recruiting | Xenon Pharmaceuticals Inc. | 360 | 2023-05-09 | 2026-11-02 |
| A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures XEN1101, Placebo - Primary Generalized Tonic-Clonic Seizures | Phase 3 | Recruiting | Xenon Pharmaceuticals Inc. | 160 | 2023-02-14 | 2026-11-02 |
| Placebo Controlled Study to Assess the Efficacy and Safety of Rapamycin in Drug Resistant Epilepsy Associated With Tuberous Sclerosis Complex Rapamycin, Placebo - Tuberous Sclerosis Complex | Phase 3 | Recruiting | Katarzyna Kotulska | 200 | 2023-01-23 | 2026-10-22 |
| Biperiden Trial for Epilepsy Prevention Biperiden, Placebo - Brain Injury Traumatic Moderate, Brain Injury Traumatic Severe | Phase 3 | Recruiting | Hospital Sirio-Libanes | 312 | 2023-01-10 | 2024-03-26 |
| Exogenous Ketone Esters for Drug Resistant Epilepsy Exogenous ketone ester - Drug Resistant Epilepsy | Phase 2 / Phase 3 | Recruiting | Sohag University | 60 | 2023-01-10 | 2024-11-27 |
| Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy Haloperidol, Chlorpromazine, Valproate - Delirium, Epileptics | Phase 2 / Phase 3 | Recruiting | M.D. Anderson Cancer Center | 42 | 2022-07-19 | 2025-11-18 |
| ONO-2017 Study Japanese Patients With Primary Generalized Tonic Clonic Seizures. Cenobamate - Epilepsy, Generalized | Phase 3 | Recruiting | Ono Pharmaceutical Co., Ltd. | 15 | 2022-07-12 | 2025-06-17 |
| Study of NRTX-1001 Neural Cell Therapy in Drug-Resistant Unilateral Mesial Temporal Lobe Epilepsy (EPIC (EPIlepsy Cell Therapy)) NRTX-1001, Sham Comparator - Mesial Temporal Lobe Epilepsy | Phase 3 | Recruiting | Neurona Therapeutics | 88 | 2022-06-16 | 2026-10-30 |
| Investigate Efficacy and Safety of Carisbamate as Adjunctive Treatment for Seizures Associated With LGS in Children and Adults Carisbamate - Seizures, Lennox Gastaut Syndrome | Phase 3 | Recruiting | SK Life Science, Inc. | 252 | 2022-04-28 | 2025-07-24 |
Showing 20 of 24. Sign in to see all of them.
Seizures (9) · Drug Resistant Epilepsy (3) · Epilepsies, Partial (3) · Lennox Gastaut Syndrome (2) · Tuberous Sclerosis (2) · Alzheimer Disease (1) · Brain Injuries (1) · Delirium (1) · Dementia (1) · Disease (1) · Down Syndrome (1) · Epilepsies, Myoclonic (1) · Epilepsy, Absence (1) · Epilepsy, Generalized (1)
Brain Diseases (24) · Central Nervous System Diseases (24) · Nervous System Diseases (24) · Pathological Conditions, Signs and Symptoms (12) · Neurologic Manifestations (10) · Signs and Symptoms (10) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Epileptic Syndromes (5) · Genetic Diseases, Inborn (5) · Epilepsy, Generalized (4) · Congenital Abnormalities (3) · Mental Disorders (3) · Neurodegenerative Diseases (3) · Hamartoma (2)
Cenobamate (2) · Levetiracetam (2) · Sirolimus (2) · Valproic Acid (2) · XEN1101 (2) · Biperiden (1) · Cannabidiol (1) · Chlorpromazine (1) · Ethosuximide (1) · Fluid Therapy (1) · Haloperidol (1) · Injections (1) · Lactic Acid (1) · Lamotrigine (1) · S-2-O-carbamoyl-1-o-chlorophenyl-ethanol (1)
Epygenix (2) · Katarzyna Kotulska (2) · Ono Pharmaceutical Co., Ltd. (2) · Rapport Therapeutics Inc. (2) · Xenon Pharmaceuticals Inc. (2) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1) · Hospital Sirio-Libanes (1) · Jazz Pharmaceuticals (1) · Johns Hopkins University (1) · M.D. Anderson Cancer Center (1) · Meyer Children's Hospital IRCCS (1) · Neurona Therapeutics (1) · Praxis Precision Medicines (1) · SK Life Science, Inc. (1) · Sohag University (1)
United States (14) · Poland (9) · Italy (7) · Spain (7) · Germany (5) · Hungary (5) · Argentina (4) · France (4) · Japan (4) · Mexico (4) · Australia (3) · Belgium (3) · Brazil (3) · Canada (3) · Czechia (3)
Amit Ray, MD (2) · Project Leader (2) · Abdelrahim A Sadek, MD, PhD (1) · David Hui, MD (1) · Eduardo Dunayevich, MD (1) · Eliana Garzon, MD, PhD (1) · Eric H Kossoff, MD (1) · Katarzyna Kotulska-Jozwiak (1) · Luiz E Mello, MD, PhD (1) · Marc Kamin, MD (1) · Vicente Villaneuva, M.D., PhD (1)
2023 (1)